Conjugates useful in the treatment of prostate cancer
US6391305B1 · kind B1 · utility
61Cited by
14References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 1999 |
| Grant date | May 21, 2002 |
| Priority date | — |
| Expiry date | Jun 28, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA), hydrophilic oligopeptide blocking groups and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.